traditional-medicine-2016_scientifictracks-workshop

27 / 38

Volume 5, Issue 2 (Suppl) J Tradi Med Clin Natur
ISSN: JTMCN, an open access journal
Page 56
Notes:
Traditional Medicine 2016
September 14-16, 2016
conferenceseries.com
September 14-16, 2016 Amsterdam, Netherlands
6th International Conference and Exhibition on
Traditional & Alternative Medicine
Drug discovery from Chinese medicines: What’s new in next?
Yibin Feng and Ning Wang
The University of Hong Kong, Hong Kong
C hinese medicine has its own science and art. To understand Chinese medicine on scientific basis and to push Chinese medicine
has become a part of world medical system. Bioscience and OMICS technologies are powerful approaches in Chinese medicine
research. In the past years, drug discovery from Chinese medicines have been acknowledged worldwide, such as artemisinin for
antimalarial and arsenic trioxide for treatment of acute promyelocytic leukemia. Actually, as a complementary and alternative
medicine, Chinese medicine rarely uses single pure compound or single herb, instead, it always uses blend of several herbs (composite
formulae, or Fufang in Chinese) to treat diseases. One of the unique advantages in Chinese medicine is that it can use known Chinese
medicinal herbs to create new composite formulae for new diseases such as SARS, new type influenza and other chronic diseases.
Facing complicated diseases, Western medicine have been also using combination therapy in modern medical practice, such as
“cocktail therapy” for AIDS, combination chemotherapy for cancer. Identification of natural origin, quality control, gut bacteria
metabolite, pharmacological effects, molecular targets and clinical trial which are caried out on international platform should be
emphasized. Some successful cases will be used as paradigms to illustrate this approach on study of Chinese medicines in in vitro and
in vivo, in this presentation.
Biography
Yibin Feng is currently an Associate Professor cum Associate Director in the School of Chinese Medicine, The University of Hong Kong. He completed his
Bachelor’s degree in Chinese Medicine from Mainland China, PhD in Molecular Medicine from Hokkaido University School of Medicine and finished Post-doctoral
research in the same University in Japan. His research interest focuses on clinical trial and experimental study for cancer, diabetes, hepatic and renal diseases by
using recently developed techniques. He has published over 200 publications in these areas and serve as an editor and reviewer for many international journals.
Yibin Feng et al., J Tradi Med Clin Natur 2016, 5:2 (Suppl)